N Engl J Med·· 12 hours agoPickScore88
Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy.
In brief
An interim analysis of the phase 3 RAINIER AIS-D08 trial showed povetacicept reduced the 24-hour urinary protein-to-creatinine ratio at week 36 by 49.8 percentage points more than placebo in patients with IgA nephropathy (95% CI -58.6 to -39.2, P<0.001).
Why it matters
The article reports proteinuria, serum biomarker, and hematuria resolution outcomes against a placebo control, enabling comparison with other IgA nephropathy regimens.
Source: N Engl J Med · doi.org